Industrial Policy & Trade Monitor· 2675 actions· ✨ 91 recent

Premier Li Qiang signed State Council Order No. 835 on 13 April 2026 promulgating the "Regulations of the People's Republic of China on Countering Foreign States' Unlawful Extraterritorial Jurisdiction" (20 articles), effective on the date of publication. The Regulations are the first State Council–level administrative regulation to operationalise the PRC's framework for identifying and countering foreign extraterritorial measures on a horizontal basis, complementing the 2021 Anti-Foreign Sanctions Law and the March 2025 AFSL implementation regulations. Article 5 establishes a State Council–led inter-agency coordination mechanism; Article 6 vests the State Council legal affairs department (the Ministry of Justice in practice) with authority to identify "improper" foreign extraterritorial measures and to grant exemptions; Article 8 authorises a new Malicious Entity List targeting foreign organisations and individuals that "promote or participate in implementing" such measures, with nine countermeasure categories spanning visa denial, asset freezing, trade restrictions and fines; Article 11 codifies an exemption-application channel under which Chinese persons facing conflicting legal demands may request approval to comply with foreign measures within a defined scope; Article 14 authorises a private right of action for harmed Chinese citizens and organisations to sue parties enforcing such measures; and Article 18 elevates enforcement beyond administrative penalties by referencing potential criminal liability.

China's State Council promulgated Order No. 818 on 28 September 2025 (effective 1 May 2026), establishing a comprehensive dual-track regulatory framework for biomedical new technologies — defined as techniques operating at the cellular or molecular level not yet clinically applied in China, covering cell therapy, gene editing, CAR-T, stem-cell, xenotransplantation, brain-computer interfaces, and nucleic-acid therapies. The regulation creates two parallel pathways: a traditional NMPA drug/device registration route and a new NHC-supervised clinical-research-to-commercialization track applicable to highly personalised or rare-disease therapies meeting staged safety and efficacy thresholds. Commercialisation under the NHC track is initially restricted to accredited Grade-3A medical institutions without full NMPA marketing approval, potentially accelerating patient access for qualifying technologies by 5–8 years relative to the standard registration pathway.

China's Unreliable Entity List (UEL) Working Mechanism, led by MOFCOM, issued Announcement [2025] No. 2 on 4 February 2025, designating PVH Group (parent of Calvin Klein and Tommy Hilfiger) and Illumina Inc. (US genomics / gene-sequencing equipment maker) as Unreliable Entities under the 2020 UEL Provisions, citing violations of normal market-transaction principles and discriminatory measures against Chinese enterprises. PVH was cited for its Xinjiang-cotton sourcing boycott (MOFCOM probe launched September 2024); Illumina was cited for restricting Chinese customers' access to gene-sequencing equipment. The announcement was issued on the same day as China's IEEPA-retaliation tariff package (10–15 % on US coal, LNG, crude oil, agricultural goods, and autos), making it the first UEL listing of a Western consumer-brand / retail company and the first combining a UEL designation with a subsequent sector-specific export prohibition (gene sequencers, imposed 28 February 2025).

China's Ministry of Commerce and General Administration of Customs jointly issued Announcement No. 33 of 2024 on 15 August 2024, imposing an export licensing regime on antimony ore, antimony metal, antimony oxides (purity ≥99.99%), organic antimony compounds, antimony hydride, indium antimonide, and gold-antimony smelting technology, effective 15 September 2024. The announcement also covers six-sided top-press equipment used in superhard-materials (diamond, cubic boron nitride) production. China accounts for approximately 47% of global antimony mine output and an estimated 75-80% of refined antimony supply; in the months following implementation, Chinese antimony export volumes fell by approximately 97% and global antimony trioxide spot prices roughly doubled.

On 15 March 2019, the Second Session of the 13th National People's Congress adopted the Foreign Investment Law of the People's Republic of China (FIL), effective 1 January 2020. The statute replaced the prior tripartite FDI regime — the 1979 Equity Joint Venture Law, the 1986 Wholly Foreign-Owned Enterprise Law, and the 1988 Contractual Joint Venture Law (collectively the "Three Laws") — with a unified legal framework covering all foreign investment in China. The FIL establishes a pre-establishment national treatment plus negative-list regime jointly administered by NDRC and MOFCOM, a Foreign Investment Information Reporting System replacing the former case-by-case approval regime, a national security review mechanism (China's CFIUS equivalent, codified at Art. 35), and Art. 22 technology-transfer prohibition protections. The State Council Implementation Regulations (Order No. 723, promulgated 26 December 2019) entered force on the same date as the FIL.